Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 76 AL 90

Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer's Disease

Prati F, Cavalli A, Bolognesi ML.

Molecules. 2016 Apr 8;21(4):466. doi: 10.3390/molecules21040466.

DYRK1A inhibition as potential treatment for Alzheimer's disease

Stotani S, Giordanetto F, Medda F.

Future Med Chem. 2016 Apr;8(6):681-96. doi: 10.4155/fmc-2016-0013. Epub 2016 Apr 13.

Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics

Rosini M, Simoni E, Caporaso R, Minarini A.

Future Med Chem. 2016 Apr;8(6):697-711. doi: 10.4155/fmc-2016-0003. Epub 2016 Apr 15.

Progress in drug development for Alzheimer's disease: An overview in relation to mitochondrial energy metabolism

Hroudová J, Singh N, Fišar Z, Ghosh KK.

Eur J Med Chem. 2016 Oct 4;121:774-784. doi: 10.1016/j.ejmech.2016.03.084. Epub 2016 Mar 30.

Targeting microglia for the treatment of Alzheimer's Disease

Wes PD, Sayed FA, Bard F, Gan L.

Glia. 2016 Oct;64(10):1710-32. doi: 10.1002/glia.22988. Epub 2016 Apr 21.

MicroRNAs as Therapeutic Targets for Alzheimer's Disease

Di Meco A, Praticò D.

J Alzheimers Dis. 2016 May 7;53(2):367-72. doi: 10.3233/JAD-160203.

Amyloid beta directed antibody for Alzheimer's disease, an evidence based meta-analysis

Li C, Ma Q, Chen S, Feng J, He Y.

Cell Mol Biol (Noisy-le-grand). 2016 Apr 30;62(4):83-7.

Targeting New Pharmacological Approaches for Alzheimer's Disease: Potential for Statins and Phosphodiesterase Inhibitors

Sallustio F, Studer V.

CNS Neurol Disord Drug Targets. 2016;15(6):647-59. doi: 10.2174/1871527315666160518123727.

Insulin and the Future Treatment of Alzheimer's Disease

Semprini R, Koch G, Belli L, Lorenzo FD, Ragonese M, Manenti G, Sorice GP, Martorana A.

CNS Neurol Disord Drug Targets. 2016;15(6):660-4. doi: 10.2174/1871527315666160518123049.

Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer's Disease

Giubilei F.

CNS Neurol Disord Drug Targets. 2016;15(6):683-9. doi: 10.2174/1871527315666160518122917.

A comparative evaluation of treatments with 17β-estradiol and its brain-selective prodrug in a double-transgenic mouse model of Alzheimer's disease

Tschiffely AE, Schuh RA, Prokai-Tatrai K, Prokai L, Ottinger MA.

Horm Behav. 2016 Jul;83:39-44. doi: 10.1016/j.yhbeh.2016.05.009. Epub 2016 May 19.

Alzheimer's disease: Is this a brain specific diabetic condition?

Rani V, Deshmukh R, Jaswal P, Kumar P, Bariwal J.

Physiol Behav. 2016 Oct 1;164(Pt A):259-67. doi: 10.1016/j.physbeh.2016.05.041. Epub 2016 May 25.

Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge

Geerts H, Dacks PA, Devanarayan V, Haas M, Khachaturian ZS, Gordon MF, Maudsley S, Romero K, Stephenson D; Brain Health Modeling Initiative (BHMI).

Alzheimers Dement. 2016 Sep;12(9):1014-1021. doi: 10.1016/j.jalz.2016.04.008. Epub 2016 May 26.

Caloric restriction: beneficial effects on brain aging and Alzheimer's disease

Van Cauwenberghe C, Vandendriessche C, Libert C, Vandenbroucke RE.

Mamm Genome. 2016 Aug;27(7-8):300-19. doi: 10.1007/s00335-016-9647-6. Epub 2016 May 30.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias